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ABSTRACT
Diffuse alveolar hemorrhage (DAH) after allogeneic hematopoietic stem cell transplantation (HSCT) is often
fatal. Standard therapy with high-dose corticosteroid is not always effective. There is paucity of data in the
literature about other potentially useful agents, such as aminocaproic acid (Amicar) in the post-transplantation
setting. We retrospectively reviewed our data on 115 consecutive patients who underwent HSCT and had
pulmonary complications, with the aim of determining the overall clinical outcome in recipients of allogeneic
transplants and in the subgroup of these patients who were treated with concomitant Solu-Medrol and
aminocaproic acid. Aminocaproic acid was added at the discretion of the attending physician. We identified 14
allogeneic transplant recipients (median age, 41 years) with 15 episodes of DAH who were treated with
Solu-Medrol (250 mg to 1 g intravenously per day). Of these, 8 patients also received concomitant aminoca-
proic acid at 1000 mg intravenously every 6 hours. Failure to improve was the most common reason for adding
aminocaproic acid. The incidence of DAHwas 12.2% (10.3% in myeloablative versus 1.9% in nonmyeloablative
recipients). The overall 100-day DAH mortality and median transplantation survival were 60% and 99 days,
respectively. Among the subset of patients treated with the combination of Solu-Medrol and aminocaproic
acid, we observed a 100-day DAH mortality and median transplantation survival of 44% and 167 days,
respectively, compared with 83% and 96.5 days in those treated with Solu-Medrol alone. The median time to
DAHwas 40.5 days, and the median time to death was 53 days in the combined treatment group compared with
29.5 days in those treated with steroid alone. There were no significant differences in coagulation parameters
between subsets. Infections (yeast, respiratory syncytial virus, herpes simplex virus, and parainfluenza) were
isolated and treated from 6 diagnostic bronchial alveolar lavage samples and were more common in the
subgroup treated with Solu-Medrol only. Respiratory failure was the documented cause of death in 89% of
patients. There were no clinically significant side effects from aminocaproic acid. Although these historically
lower DAH outcomes are intriguing, prospective studies are needed to confirm the role of aminocaproic acid
in DAH occurring in the allogeneic transplantation setting.
© 2006 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Allogeneic hematopoietic stem cell transplantation
HSCT) has become an important treatment modality
or a number of hematologic malignancies and often
rovides the only curative option. Worldwide, nearly
0 000 allogeneic transplantations were performed for
arious malignancies in 2004 [1]. Pulmonary compli- iations occur in 30%-60% of allogeneic transplant
ecipients and are frequent causes of mortality [2,3].
iffuse alveolar hemorrhage (DAH) is a recognized
ulmonary complication in the allogeneic transplan-
ation setting, although it was ﬁrst described in autol-
gous bone marrow transplantation [1]. Although the
ncidence of DAH in autologous and allogeneic trans-
949
p
[
b
t
o
a
r
3
o
p
a
t
m
t
a
D
h
f
u
t
i
t
o
o
t
t
t
[
P
a
e
o
c
e
M
P
r
m
H
N
r
p
c
w
t
w
a
t
M
u
a
s
D
a
t
p
w
e
b
n
n
d
h
a
n
S
o
D
d
r
T
s
M
T
T
A
G
E
T
S
A
D
T
I
A
S. O. Wanko et al.950lantations are 5%-21% and 2%-17%, respectively
3-11], the mortality rates for allogeneic recipients can
e up to 100% [2-7,10-12]. In their review of 48 pa-
ients, Afessa and colleagues [2] reported a mortality rate
f 28% in the autologous group compared with 70% in
llogeneic transplant recipients (P  .0040). In this se-
ies, mortality was higher (70%) for DAH that occurred
0 days after transplantation compared with DAH that
ccurred in the ﬁrst 30 days. The risk factors and
athogenesis for DAH are not well characterized but
re believed to be multifactorial. Age 40 years, in-
ensity of preparative regime, presence of proinﬂam-
atory cells and cytokines, thrombocytopenia, infec-
ions, late engraftment, and graft-versus-host disease
re some of the risk factors often cited [3,5,13,14]
The usual management approach for suspected
AH involves bronchoscopy for diagnosis, low- to
igh-dose corticosteroids, and mechanical ventilation
or acute respiratory failure. Despite the widespread
se of corticosteroids in DAH, its mechanism of ac-
ion, efﬁcacy, and optimal dose have not been deﬁned
n a prospective fashion. Anecdotal evidence suggests
hat clinical responses to corticosteroids in this setting
ccur within 48 hours after therapy. In part, because
f the lack of uniformity in dose selection and dura-
ion of treatment, response to corticosteroid is often
ransient, resulting in rebleeding, progressive respira-
ory failure, and death, even when high doses are used
7,10]. Aminocaproic acid (Amicar, Wyeth-Ayerst,
A) is an antiﬁbrinolytic agent that has been used to
chieve hemostasis in various settings, such as dental
xtractions, after biopsies, cardiac surgery, and solid
rgan transplantation [15-19]. However, there is pau-
ity of data in the literature about its clinical use or
fﬁcacy in DAH that occurs after HSCT.
ETHODS
atients and Study Design
Electronic medical, bronchoscopic, and pharmacy
ecords of 115 consecutive patients with hematologic
alignancies who had pulmonary complications after
SCT at Duke University Medical Center (Durham,
C) between August 1999 and January 2005 were
eviewed with the aim of identifying allogeneic trans-
lant recipients with DAH, their overall clinical out-
ome, and the outcome in the subsets of these patients
ho were treated with aminocaproic acid in combina-
ion with standard corticosteroids. Fourteen patients
ith 15 episodes of DAH (Table 1) were identiﬁed
nd analyzed descriptively as a group and based on the
ype of DAH therapy they received. High-dose Solu-
edrol (Pﬁzer, NY) is the standard therapy for DAH
sed by our transplant group, whereas aminocaproic
cid was added at the discretion of the attending phy-
icians. piagnosis and Treatment of DAH
Table 2 lists the bronchoscopic characteristics for
ll patients. DAH was diagnosed when patients’ symp-
oms and/or abnormal radiographs, including com-
uted tomograms, led to bronchoscopic evaluation, in
hich progressively bloodier return was observed with
ach aliquot of bronchial alveolar lavage (BAL). All
ronchoscopies were performed by a single pulmo-
ologist (RJF), which enhanced consistency in diag-
osis and therapeutic recommendation. The usual
ose and schedule of Solu-Medrol was 250 mg every 6
ours tapered by 50% every 3 days, and aminocaproic
cid was administered at a dose of 1000 mg intrave-
ously every 6 hours.
tatistical Analysis
The study group of 14 patients (with 15 episodes
f DAH) was analyzed descriptively. The 100-day
AH mortality was deﬁned as death in the ﬁrst 100
ays after the diagnosis of DAH. The time to death
epresents the period from DAH diagnosis to death.
ransplantation survival represents the duration from
tem cell infusion (day 0) to patients’ censure. Kaplan-
eier estimates were used to calculate median trans-
able 1. Patient Characteristics
otal number of patients 14
ge, median (range) 41 (20-54)
ender
Male 11
Female 3
pisodes of DAH 15
ime of DAH diagnosis (days), median (range) 40.5 (11-177)
olu-Medrol treatment per episode 15/15
minocaproic acid treatment per episode 9/15
Number of days on aminocaproic acid,
median (range)
Indication for aminocaproic acid 17 (1-49)
No improvement on Solu-Medrol 8/9
Concurrent with Solu-Medrol 1/9
iagnosis
AML 6
ALL 3
NHL 2
CLL 1
MDS-AML 1
Breast cancer 1
ype of transplant
Ablative 12
Non-myeloablative 2
CU admission
Without intubation 1
With intubation 3
ML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic
leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lympho-
blastic leukemia; MDS-AML, myelodysplastic syndrome; ICU,
intensive care unit.lantation survival days.
Re
r
D
m
m
y
p
1
v
p
n
t
t
w
a
o
d
a
D
r
s
M
l
t
t
e
w
T
f
t
a
b
o
t
D
w
t
o
t
M
t
t
w
c
o
i
r
o
t
i
q
c
d
a
n
f
a
c
n
m
B
o
c
T
p
s
i
m
b
a
c
f
i
r
s
b
o
n
c
c
e
T
N
I
M
P
M
P
B
W
I
P
Diffuse Alveolar Hemorrhage 951ESULTS
Patients’ characteristics are listed in Table 1. Fifteen
pisodes of DAH occurred in 14 allogeneic transplant
ecipients (11 men and 3 women). The incidence of
AH was 12.2% (14 of 115), with 10.3% (12 of 115) in
yeloablative compared with 1.9% (2 of 115) in non-
yeloablative transplant recipients. Median age was 41
ears (range, 20-54 years) and time to DAH after trans-
lantation was 40.5 days (range, 11-177 days). Overall
00-day DAHmortality andmedian transplantation sur-
ival were 60% and 99 days, respectively. In the subset of
atients treated with concomitant Solu-Medrol and ami-
ocaproic acid, the 100-day DAH mortality and median
ransplantation survival were 44% and 167 days, respec-
ively, compared with 83% and 96.5 days in those treated
ith Solu-Medrol alone. Median times to death were 53
nd 29.5 days in the combined treatment and steroid-
nly groups, respectively. Respiratory failure was the
ocumented cause of death in 89% of patients (8 of 9)
nd speciﬁc cause was not listed for 1 patient, although
AH was the terminal event. Median coagulation pa-
ameters (Table 2) were near the normal range and were
imilar across subsets. Two patients (1 treated with Solu-
edrol and the other with combined therapy) were on
ow-dose heparin (100 U · kg1 · d1) at the time of
heir DAH diagnosis. Infectious agents (yeast, respira-
ory syncytial virus, herpes simplex virus, and parainﬂu-
nza) were isolated from 6 diagnostic BAL samples and
ere more common in the Solu-Medrol-only subgroup.
here were no major, clinically apparent side effects
rom the addition of aminocaproic acid, although 1 pa-
able 2. Bronchoscopic Characteristics
umber of episodes 15
ndication for bronchoscopy per episode
Hypoxia/dyspnea 13
Abnormal radiograph 15
Hemoptysis 3
edian number of lobes lavaged 2
reprocedure platelets count (103),
median (range) 40 (12-99)
edian (PT/INR/PTT)
All patients 14.2/1.2/29.7
Steroid-treated patients 13.8/1.2/29.9
Steroids and aminocaproic acid 15.4/1.2/28.0
rogressive blood return on BAL
per episode 15
AL RBC count, median (range) 12,069 (50-143,750)
BC count, median (range) 40 (10-5650)
nfectious agents isolated per episode 6
Yeast 3
HSV 1
Yeast, parainfluenza, RSV 1
Parainfluenza, RSV 1
T indicates prothrombin time; INR, international normalized ratio;
PTT, partial thromboplastin time; RBC, red blood cell; WBC,
white blood cell; HSV, herpes simplex virus; RSV, respiratory
syncytial virus.ient had recurrent DAH in this group. Dyspnea and Bbnormal radiograph were themost common reasons for
ronchoscopy. Poor clinical improvement after 48 hours
f Solu-Medrol therapy was the primary reason for ini-
iating aminocaproic acid.
ISCUSSION
In this study of allogeneic transplant recipients
ith DAH, the overall mortality of 60% is similar to
he historically reported mortality of 70% from
ther series [2,5,7]. However, in the subset of patients
reated with concomitant aminocaproic acid and Solu-
edrol, we observed differences in 100-day DAH mor-
ality and overall survival of 44% and 167 days, respec-
ively, compared with 83% and 96.5 days in those treated
ith Solu-Medrol alone. Although intriguing, we cannot
onﬁdently attribute these ﬁndings to the solitary effects
f aminocaproic acid without further prospective exam-
nation. Nonetheless, to our knowledge, this is the ﬁrst
eported series on the use of aminocaproic acid for DAH
ccurring in the allogeneic hematopoietic transplanta-
ion setting. To be sure, this study provokes several
mportant clinical questions that are addressed in subse-
uent paragraphs, which include controversy about the
riteria for DAH diagnosis, the clinical signiﬁcance of
iagnostic BAL isolated infectious agents, the efﬁcacy,
nd dose of corticosteroids, the toxicity of using ami-
ocaproic acid, and the role of other potentially con-
ounding factors seen in the period immediately after
llogeneic transplantation.
DAH remains a syndrome without standardized
linical, radiographic, or laboratory markers for diag-
osis. Although we used patients’ symptoms, abnor-
al radiographic ﬁndings, and progressive bloody
AL on bronchoscopy as the basis for DAH diagnosis,
ther investigators have advocated stricter diagnostic
riteria similar to those reported in autopsy series.
he latter are difﬁcult to duplicate and use in clinical
ractice without compromising patient care. For in-
tance, the diagnostic criteria used by Agusti et al [13]
n their autopsy review of DAH in allogeneic bone
arrow transplant recipients required the presence of
lood in 30% of the evaluated lung tissue and the
bsence of infection or other pathologic changes that
ould account for DAH. Such a criterion may not be
easible in living patients, even when overt hemoptysis
s the initial presenting symptom. Thus, abnormal
adiographs and patients’ symptoms remain the initial
urrogate evidence of DAH. Similarly, progressive
loodier return of BAL on bronchoscopy, which has
ften been held as a higher criterion for DAH diag-
osis, also has its limitations. Of the patients with
onﬁrmed DAH in the autopsy series by Agusti and
olleagues [13] who had undergone bronchoscopic
xamination within 1 week of death, 50% had normal
AL ﬂuid, and 54% of those without DAH had
b
o
b
e
d
a
t
a
T
i
p
b
a
f
p
m
f
p
t
f
o
D
h
c
p
w
a
c
e
t
r
p
t
i
b
m
r
a
a
D
p
e
ﬂ
d
k
v
c
b
f
n
u
p
f
c
t
D
b
c
s
7
d
A
M
i
m
w
(
i
v
w
m
c
h
b
s
m
y
f
M
t
n
t
c
h
s
d
e
n
t
p
b
a
d
s
a
c
o
t
o
ﬁ
i
a
s
a
t
t
t
e
S. O. Wanko et al.952loody BAL ﬂuid. Thus, descriptive bloodier return
n BAL, which is not highly speciﬁc for DAH, should
e viewed in association with other suggestive clinical
vidence of DAH. Therefore, DAH remains a clinical
iagnosis, guided mostly by high index of suspicion.
In its purest form, DAH occurs in the absence of
ny confounding infectious agents. However, infec-
ious agents are often isolated from diagnostic BAL
nd lead to confusion about their causative role in DAH.
his is especially true when other evidence of clinical
nfection, such as fever, productive cough, leukocytosis,
arallel isolation of similar infectious agent from other
ody samples, or purulent bronchoscopic samples, are
bsent. It is known that infectious agents can be isolated
rom diagnostic BAL in patients without clinically ap-
arent infections, whereas those with infectious pneu-
onia often have negative BAL [3,5,14]. Although in-
ections are believed to cause DAH, there are no
rospective studies that have investigated whether infec-
ious agent isolated from BAL are directly responsible
or DAH or whether treating all such infections reduces
r eliminates the high mortality rates associated with
AH. In this review, yeast, respiratory syncytial virus,
erpes simplex virus, and parainﬂuenza were the most
ommon infections identiﬁed in 6 diagnostic BAL sam-
les and occurred more commonly in patients treated
ith only Solu-Medrol. Like most centers, our group is
ggressive and proactive when treating pharmacologi-
ally treatable infections isolated from diagnostic BAL,
ven when their clinical relevance is uncertain. Even so,
he issue of infectious DAH and the effect treatment will
emain unsettled in the absence of good preclinical and
rospective clinical studies. The latter will, among other
hings, entail repeating bronchoscopies to conﬁrm erad-
cation of infectious agents to truly assess the correlation
etween eradication of BAL-isolated infection andDAH
ortality [8,14,20]. For 89% of patients in this study,
espiratory failure was the contributing cause of death
nd 1 patient did not have documented cause of death,
lthough DAH was the terminal event.
The mechanisms of action of corticosteroids in
AH is unknown but may include modulation of
roinﬂammatory conditions induced by lung alveolar
ndothelial swelling, thrombotic microangiopathy, in-
ammatory cells and cytokines, and graft-versus-host
isease [21-27]. In contrast, aminocaproic acid is a
nown antiﬁbrinolytic agent with proved efﬁcacy in
arious spontaneous or procedure-related bleeding
onditions [15-18,28-31]. However, the nature of the
alance between proﬁbrinolytic and antiﬁbrinolytic
actors in the allogeneic transplantation setting has
ot been well characterized, leading us to only spec-
late that this balance is probably weighted toward
roﬁbrinolysis. The reported efﬁcacy of corticosteroid
or DAH in the literature is mixed. The rapidity of
linical response after therapy is also unknown, al-
hough anecdotal evidence suggests that responses in HAH usually occur within 48 hours. In allogeneic
one marrow transplant recipients treated with corti-
osteroids, Lewis and colleagues [7] reported a tran-
ient response rate of 67% and a mortality rate of
4%, leading the investigators to conclude that high-
ose corticosteroids have limited efﬁcacy for DAH.
lthough high-dose therapy usually entails Solu-
edrol, given at 1 g/day, lower doses have been stud-
ed. Metcalf et al [8] assessed the efﬁcacy and dosing of
ethylprednisolone in 3 patient groups: those treated
ith supportive care (no treatment) versus low dose
30 mg daily) versus high dose (30 mg daily). The
nvestigators found signiﬁcantly improved overall sur-
ival (P  .0005) in the high-dose group compared
ith the other 2 groups. The prehospital discharge
ortality was 91% for the supportive and low-dose
orticosteroids groups compared with 67% in the
igh-dose group. There were no survival differences
etween the low-dose and supportive arms of the
tudy. Thus, although methylprednisolone doses 30
g daily are commonly used, prospective studies have
et to determine the optimal doses of corticosteroids
or DAH. Our group commonly uses high-dose Solu-
edrol at 250 mg intravenously every 6 hours, with a
aper of 50% every 3 days.
The known side effects of aminocaproic acid are
umerous and range from serious events, such as
hrombosis, seizures, strokes, and dysrhythmias, to
ommon side effects, such as headaches, cytopenias,
ypertension, nausea, bleeding, and myopathy. In this
tudy, none of these major side effects was reported
uring the course of aminocaproic acid therapy. How-
ver, 1 patient had recurrence of DAH, which could
ot be directly attributable to this agent. As is usually
he case after allogeneic transplantation, nausea, cyto-
enias, hypertension, and headaches were common
ut did not worsen with initiation of aminocaproic
cid. There was no signiﬁcant abnormal coagulation
isparity between subsets (Table 2).
The major limitations of this study include its
mall sample and retrospective nature, which did not
llow for a more rigorous control of other complex
linical factors that may have contributed to poor
utcome in the period immediately after allogeneic
ransplantation. Therefore, we make conclusions from
ur observations cautiously until prospectively con-
rmed. Even so, the importance of our result primar-
ly relates to difﬁcult practical patient care issues after
llogeneic transplantation, where clinical decisions
uch as failure to add a potentially useful agent such as
minocaproic acid in patients clinically unresponsive
o corticosteroids or rapidly deteriorating might lead
o avoidable adverse consequences.
In summary, DAH remains a clinical diagnosis
hat requires a high index of suspicion to identify,
specially in the complex clinical setting of allogeneic
SCT. The signiﬁcance of infectious agents often
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Diffuse Alveolar Hemorrhage 953solated from diagnostic BAL remains unclear, al-
hough these are treated routinely. Despite wide-
pread use of high-dose corticosteroids for DAH,
ortality remains high, making the search for alter-
ative or adjunct therapies necessary. In this small
tudy, we have documented the interesting observa-
ion that addition of aminocaproic acid to Solu-
edrol may improve DAH mortality and survival
eyond what had been historically reported in other
eries. Additional studies are needed to prospectively
etermine the coagulation milieu, the optimal dose of
olu-Medrol, and the contribution of aminocaproic
cid to these clinical results.
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